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Abstract
Background: Vascular endothelial growth factor-A (VEGF-A) and chemokne ligand-2 (CCL2) levels have been
examined in Amyotrophic Lateral Sclerosis (ALS) patients in Western countries. We measured these values in North
Indian ALS patients, since these patients display considerably enhanced survival duration.
Methods: Sporadic ALS patients were included on the basis of El Escorial criteria. VEGF-A and CCL2 levels were
analyzed in serum and cerebrospinal fluid (CSF) of 50 ALS patients using enzyme linked immunosorbent assay
(ELISA) and compared with normal controls. Their levels were adjusted for possible confounders like cigarette
smoking, alcohol and meat consumption.
Results: Contrary to previous studies, VEGF-A was found to be elevated significantly in serum and CSF in ALS
patient population studied. We also found an increase in CCL2 levels in CSF of these ALS patients. Serum and CSF
from definite ALS revealed higher VEGF-A as compared to probable and possible ALS. CCL2 was unaltered
between definite, probable and possible ALS. Univariate and multivariate analysis revealed a lack of association of
smoking, alcohol and meat consumption with VEGF-A and CCL2 levels.
Conclusions: VEGF-A upregulation may indicate an activation of compensatory responses in ALS which may reflect
or in fact account for increased survival of North Indian ALS patients after disease onset. The intrathecal synthesis
of CCL2 suggests the involvement of adult neural stem cells and microglial activation in ALS pathogenesis which
needs further investigation.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disorder with genetic and clinical heterogeneity.
Existing evidence suggests that Vascular endothelial
growth factor-A (VEGF-A) delivery delays the onset and
progression of ALS in superoxide dismutase-1 (SOD1)
mutated transgenic mouse model by activating PI3-K/
Akt anti apoptotic pathway [1,2]. VEGF-A also shown to
be involved in proliferation and differentiation of adult
mouse neural progenitor’s cells [3]. On the other hand,
chemokine ligand-2 (CCL2), a proinflammatory mole-
cule, enhances microglial recruitment after injury to
central nervous system (CNS) and exacerbates ALS [4].
It has been observed that CCL2 knockout mice have
reduced involvement of immune cells and are resistant
to stroke and autoimmune encephalomyelitis [5,6].
Reports suggest that VEGF-A165,am a j o ri s o f o r mo f
VEGF-A, and CCL2 may interact in synergistic manner
to mount a response to disease [7]. We therefore
hypothesized that VEGF-A-CCL2 axis plays a crucial
role in ALS pathogenesis and could be a target for
development of future therapy for ALS.
Subjects and methods
50 patients diagnosed with ALS were recruited after
obtaining informed consent as per institute ethical com-
mittee guidelines (No. 7055-PG-1Tg-05/4348-50). All
patients were born in Northern India. Of the patients
examined, 25 patients fulfilled the “El Escorial criteria”
for definite ALS, 15 individuals fulfilled for probable
and 10 patients as possible ALS at the time of sample
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patients had respiratory insufficiencies alongwith
orthopnea and dyspnea, although none of the patients
needed respiratory support. There were 42 cases of limb
and 8 cases of bulbar onset ALS. Patients with history
of stroke, pre-eclampsia, diabetic neuropathy, glaucoma,
diabetes, those who have been receiving riluzole, anti
inflammatory drugs, antioxidants or other treatment
were excluded. 50 genetically unrelated healthy normal
controls without any complaints of hypertension, dia-
betes, heart disease etc were also included. Cerebrosp-
inal fluid (CSF) from 42 subjects without any CNS
disorders but undergoing routine spinal anesthesia for
surgery was collected and considered control sample.
Subjects were categorized as cigarette smokers and
never smokers, alcohol consumers and nonalcoholics,
vegetarian and non-vegetarian (or meat consumers)
through a questionnaire [9]. The characteristics of sub-
jects have been reproduced in Table 1.
Serum was separated from 4.0 ml blood collected in
serum separator tube (BD Biosciences, USA). ~2.0 ml
CSF was drawn in a sterilized container. Serum and CSF
was stored at -80°C until assayed.
Serum VEGF-A, CCL2 and CSF CCL2 was measured
using Quantikine sandwich enzyme linked immunosor-
bent assays (ELISA; R&D systems, USA) and read at 450
nm in 680XR microplate reader (Biorad, USA). CSF
VEGF-A levels were quantitated with QuantiGlo chemi-
luminescent assay (R&D systems), and read as relative
light units in luminometer (Biotek, USA). ELISA kits for
VEGF-A measured unbound natural human VEGF-A165
splice variant.
Mann Whitney U test and one-way analysis of var-
iance (ANOVA) followed by Fisher’s least significant dif-
ference (LSD) post hoc analysis was applied to analyze
skewed and normally distributed data respectively. As
smoking, alcohol and meat consumption may affect
VEGF-A and CCL2 levels, crude odds ratio (OR) of
their association was evaluated by univariate logistic
r e g r e s s i o n .A d j u s t e dO Rt oi n v e s t i g a t ei n d e p e n d e n t
effect of these covariates was computed using multivari-
a t el o g i s t i cr e g r e s s i o na n dc
2 ( c h is q u a r e )t e s tw a sp e r -
formed to calculate p-value. p-value was considered
significant at ≤ 0.05. Statistical analysis was performed
by statistical package and service solutions 16.
Results
ELISA indicates elevated serum VEGF-A in ALS as
compared to controls (Figure 1A; p = 0.046). Median
CSF VEGF-A concentration was significantly higher in
ALS patients than controls (Figure 1B; p = 0.0001). No
difference in serum CCL2 was observed between ALS
and controls (Figure 2A; p > 0.05). However, CSF CCL2
was found increased in ALS as compared to controls
(Figure 2B; p = 0.003). There was elevated serum
VEGF-A in definite ALS in comparison to controls,
probable and possible ALS (Figure 3A; p = 0.015, p =
0.033 and p = 0.017 respectively). Similarly, CSF from
definite ALS was reported to have statistically higher
VEGF-A than controls, probable and possible ALS (Fig-
ure 3B; p = 0.0001, p = 0.018 and p = 0.017 respec-
tively). However, serum and CSF CCL2 levels did not
differ among definite, probable and possible ALS (Figure
4A-4B; p > 0.05).
No association of cigarette smoking, alcohol and meat
consumption with VEGF-A (Table 2) and CCL2 (data
not shown) levels in serum and CSF was observed upon
univariate and multivariate analysis.
Discussion
Our study of North Indian ALS patients represents a
unique opportunity to understand the disease from a
distinct genetic perspective, given that these patients
bring a peculiar spectrum of extended life expectancy in
comparison to Western counterparts [10]. An earlier
Indian study has reported the median survival duration
of 114.83 ± 25.9(SE) months in 1153 ALS patients after
disease onset. The mean survival duration of male
patients was 110 ± 27.4(SE) months which was not sig-
nificantly different from mean survival duration of


















ALS 47.4 ± 12.4 38/12 46.2 ± 12.8 19.0 ± 12.7 12 12 20 0.43 ± 0.2 48.2 ± 26.7
Controls
(Serum)
40.0 ± 12.8 39/11 10 14 27 48.7 ± 28.7
Controls
(CSF)
43.4 ± 17.1 35/07 08 09 10 0.42 ± 0.1
Clinical and demographic summary of ALS cases and controls. n, Number; M, male; F, female; y, years; mo, months; g, gram; l, litre; CSF, cerebrospinal fluid; Age,
age of onset, duration of disease, CSF and serum total protein are indicated as mean ± standard deviation (SD). † One way ANOVA followed by LSD post hoc
analysis showed that mean age and, mean concentration of total protein in serum and CSF did not differ significantly among the groups (p > 0.05). ‡ Duration of
disease is the interval between appearance of first symptom of ALS and collection of sample. ALS subjects were asked to provide all clinical and demographic
details at the age of disease-onset.
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Page 2 of 8Figure 1 Level of VEGF-A in serum (A) and CSF (B) of ALS patients and normal controls. Boxes include values from first quartile (25th
percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th percentile respectively. The thick horizontal linei n
the box represents median for each dataset. Levels of VEGF-A were normalized to total serum and CSF protein respectively. Outliers and extreme
values are shown in circles and asterisk respectively. # indicates significant difference (p < 0.05) between the given conditions. Data was analyzed
by Mann Whitney U Test. ALS, Amyotrophic Lateral Sclerosis; VEGF-A, vascular endothelial growth factor-A; pg, picogram; μg, microgram.
Figure 2 Level of CCL2 in serum (A) and CSF (B) of ALS patients and normal subjects. Boxes include values from first quartile (25th
percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th percentile respectively. The thick horizontal line
in the box represents median for each dataset. Levels of CCL2 were normalized to total protein in the serum and CSF samples. Outliers and
extreme values are shown in circles and asterisk respectively. # indicates significant difference (p < 0.05) between the given conditions. Data was
analyzed by Mann Whitney U Test. ALS, Amyotrophic Lateral Sclerosis; CCL2, chemokine ligand 2; pg, picogram; μg, microgram.
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patients from USA and Europe make up 3-6 years of
survival time [12,13].
The increased serum VEGF-A in our ALS patients is
consistent with the existing report [14], and suggests
that serum is a pathophysiologically relevant fluid in
ALS, particularly in definite ALS, however, a few other
studies have failed to observe significant difference in
plasma and serum VEGF-A levels in ALS patients
[15,16].
The elevated CSF VEGF-A in ALS indicates possible
presymptomatic initiation of pathological events
and intrathecal production from degenerating motor
neurons, which is contrary to existing study where
decreased VEGF-A165 dependent neuroprotection in
ALS, due to reduced CSF VEGF-A, has been suggested
[15]. Since the impaired VEGF-A expression in early
ALS negatively influences the clinical outcome of the
disease [15], its upregulation suggests a compensatory
response, contributing to prolonged survival of our ALS
patients. It is speculated that North Indian ALS patients
generate increased VEGF-A or stimulate glutamate
receptor-2 expression to ameliorate excitotoxicity
[17,18]. We are unable to conclude whether this
response is a consequence of amyotrophy, hypoxia,
dietary or other environmental factors, or some subtle
genetic differences [14,15].
Further analysis shows significantly increased VEGF-A
in 11 ALS patients with respiratory dysfunction indicat-
ing a possible association withh y p o x i a( F i g u r e5 A - 5 B ;
Table 3). Elevated VEGF-A in serum and CSF of definite
ALS suggests extensive involvement of neuroaxis and
relatively higher degree of neurodegeneration and regen-
eration than probable and possible variants. No signifi-
cant difference in median disease duration between
definite [14(4-36) months], probable [16(3-72) months]
and possible ALS [14(9-24) months] cases was observed.
It must be pointed out that while the disease duration
was accurately documented, the actual survival time of
patients after disease onset could not be ascertained.
Intrathecal secretion of CCL2 may offer neuroprotec-
tion against glutamate excitotoxicity either by reducing
N-Methyl-D-aspartate (NMDA)-dependant release of
glutamate and/or increasing astrocytes efficiency to clear
synaptic cleft glutamate [19]. CCL2 promotes CCR2 and
CCR5 expressing C17.2 neural progenitor cell migration
and their differentiation into neuronal and glial pheno-
type [20,21]. CCL2 is also known to be angiogenic and
participates in hypoxia inducible factor-1a induced
VEGF-A expression [7]. Likewise, VEGF-A upregulates
Figure 3 Level of VEGF-A in serum (A) and CSF (B) of definite ALS, probable ALS, possible ALS patients and normal subjects.B o x e s
include values from first quartile (25th percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th
percentile respectively. The thick horizontal line in the box represents median for each dataset. Levels of VEGF-A were normalized to total
protein in the serum and CSF samples. Outliers and extreme values are shown in circles and asterisk respectively. # indicates significant
difference (p < 0.05) between the given conditions. Data was analyzed by Mann Whitney U Test. ALS, Amyotrophic Lateral Sclerosis; VEGF-A,
vascular endothelial growth factor-A; pg, picogram; μg, microgram.
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extracellular signal-regulated kinases (ERK) pathways in
microglia [22]. Hence, it is possible that VEGF-A-CCL2
axis plays a crucial role in ALS pathogenesis.
The comparison between normal and neurological con-
trols showed relatively pronounced increase in VEGF-A
and CCL2 in the latter thus limiting the utility of these
as biomarkers in ALS, however, further analysis of this
data is being conducted by including homogeneous
Parkinson’s disease controls instead of the heterogeneous
neurological controls used (data not shown).
Regardless of the reason, it is clear that elevated
VEGF-A is associated with prolonged survival of Indian
ALS patients. At this time, we have no explanation for
the basis of this finding, but discuss its therapeutic
potential. Increasing brain levels of VEGF-A by genetic
engineering, direct infusion or stem cell transplantation
may provide limited but significant prolonged life
Figure 4 Level of CCL2 in serum (A) and CSF (B) of definite ALS, probable ALS, possible ALS patients and normal subjects.B o x e s
include values from first quartile (25th percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th
percentile respectively. The thick horizontal line in the box represents median for each dataset. Levels of CCL2 were normalized to total protein
in the serum and CSF samples. Outliers and extreme values are shown in circles and asterisk respectively. No significant difference (p > 0.05) was
found between the given conditions. Data was analyzed by Mann Whitney U Test. ALS, Amyotrophic Lateral Sclerosis; CCL2, chemokine ligand 2;
pg, picogram; μg, microgram.
Table 2 Crude and adjusted OR for VEGF-A levels in smokers, alcohol and meat consumers
OR (95% CI)
† p* Adj. OR (95% CI)
‡ p*
Serum VEGF-A
Smoking 1.4 (0.4-4.5) 0.5 0.7 (0.2-2.5) 0.6
Alcohol consumption 0.7 (0.2-2.2) 0.6 0.9 (0.3-3.0) 0.9
Meat consumption 1.5 (0.5-3.9) 0.4 1.4 (0.5-4.0) 0.7
CSF VEGF-A
Smoking 1.4 (0.4-4.5) 0.4 0.7 (0.2-2.5) 0.6
Alcohol consumption 0.7 (0.2-2.2) 0.4 0.9 (0.3-3.0) 0.8
Meat consumption 1.5 (0.5-3.9) 0.2 1.4 (0.5-4.0) 0.2
Never smoking/Nonalcoholic/Vegetarian** 1.0 1.0
† Univariate logistic regression was used to evaluate crude OR. ‡ Multivariate logistic regression has been used to adjust the effect of smoking on VEGF-A levels
with alcohol and meat consumption as covariates. Likewise, effect of alcohol is adjusted for smoking and meat consumption, and meat consumption is corrected
for smoking and alcohol intake. * c
2 (chi square test) was used to test the level of significance. ** Never smoking, nonalcoholic and vegetarian diet is considered
as reference group. OR, odds ratio; CI, confidence interval; Adj, adjusted.
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dies have documented that aside from promoting revas-
cularization, VEGF-A is a potent vasodilator, as well as
attractant of marrow stromal cells and to some extent,
hematopoietic stem cells [23]. Our results suggest that
etiological factor VEGF-A needs to be augmented along-
with regulation of inflammation, as noted here by con-
sistently increased CCL2, either by hematopoietic cell
transplantation or by defining other neurotrophic and
proinflammatory factors involved in ALS. Localized
stem cell therapy designed to restore lost neural tissue
presents subsequent therapeutic interventions [24]. Such
a multifaceted approach will be helpful in presympto-
matic identification of individuals who will develop ALS.
These individual thus can be treated to prevent ALS
from rapidly overwhelming the host defenses.
Figure 5 Level of VEGF-A in serum (A) and CSF (B) of ALS patients with respiratory dysfunction. Boxes include values from first quartile
(25th percentile) to third quartile (75th percentile). Lower and upper error bar refers to 10th and 90th percentile respectively. The thick
horizontal line in the box represents median for each dataset. Levels of VEGF-A were normalized to total serum and CSF protein respectively.
Outliers are shown in circles. # indicates significant difference (p < 0.05) between the given conditions. Data was analyzed by Mann Whitney U
Test. ALS, Amyotrophic Lateral Sclerosis; VEGF-A, vascular endothelial growth factor-A; pg, picogram; μg, microgram.
Table 3 Clinical summery of 11 ALS patients with respiratory dysfunction
ALS subjects El Escorial criteria ALSFRS-R Impairment Disease duration at sample collection (mo)
‡
Patient 1 Definite 27 Moderate 12
Patient 2 Definite 23 Severe 12
Patient 3 Definite 18 Severe 24
Patient 4 Definite 16 Severe 18
Patient 5 Definite 29 Moderate 12
Patient 6 Definite 29 Moderate 04
Patient 7 Definite 29 Moderate 09
Patient 8 Definite 31 Moderate 08
Patient 9 Definite 35 Moderate 24
Patient 10 Probable 34 Moderate 12
Patient 11 Probable 35 Moderate 30
ALSFRS-R: ALS functional rating score-revised; Impairment was measured with ALSFRS-R. ‡ Duration of disease is the interval between appearance of first
symptom of ALS and collection of sample. Median disease duration in patients with respiratory dysfunction is 12(4-30) months whereas median durationo f
disease was 17(3-72) months in patients without respiratory dysfunction, although the observed difference was not significant upon Mann-Whitney U analysis (p
> 0.05).
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meat consumption with VEGF-A and CCL2 enhances
the credibility of the results since these confounders
increased the endpoints assessed but did so regardless
of ALS status of the individual studied. The current
report thus reliably indicates that ALS is associated with
increased VEGF-A and CCL2 providing a foundation for
subsequent studies to examine if this result is a factor in
the enhanced survival of Indian ALS patients and if so,
the mechanisms involved.
Conclusions
Our study supports that VEGF-A and CCL2 may be
involved in enhancing the survival time of sporadic ALS
patients, however, comprehensive understanding of
growth factors network is required to unveil diagnostic
and therapeutic efficacy of these molecules.
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